Prognosis for patients with metastatic breast cancer who achieve a no‐evidence‐of‐disease status after systemic or local therapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|24|4324-4332

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.24, 2015-12, pp. : 4324-4332

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Primary systemic therapy in patients with breast cancer: rationale of use and magnitude of evidence

By Puglisi Fabio   Minisini Alessandro   Piga Andrea  

Therapy, Vol. 1, Iss. 1, 2004-09 ,pp. : 91-100

Future Medicine

Access to resources Recommend Favorite

Are There Breast Cancer Patients with Node-Negative Small Tumours, Who Do Not Benefit from Adjuvant Systemic Therapy?

By  

Oncology, Vol. 92, Iss. 6, 2017-03 ,pp. : 317-324

Karger

Access to resources Recommend Favorite

Systemic Therapy of Metastatic Breast Cancer: The Truth Beyond the Clinical Trials

By  

Oncology, Vol. 76, Iss. 4, 2009-02 ,pp. : 247-253

Karger

Access to resources Recommend Favorite

Systemic immune‐inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration‐resistant prostate cancer patients

By  

THE PROSTATE, Vol. 78, Iss. 4, 2018-03 ,pp. : 250-256

John Wiley & Sons Inc

Access to resources Recommend Favorite

Global abnormalities in lymphatic function following systemic therapy in patients with breast cancer

By  

BRITISH JOURNAL OF SURGERY, Vol. 102, Iss. 5, 2015-04 ,pp. : 534-540

John Wiley & Sons Inc

Access to resources Recommend Favorite